Aadi bioscience reports first quarter 2022 financial results and provides a corporate update

Los angeles, may 12, 2022 (globe newswire) -- aadi bioscience, inc. (nasdaq: aadi), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mtor pathway genes, today announced financial results for the first quarter of 2022 and provided a corporate update.
AADI Ratings Summary
AADI Quant Ranking